- Home
- STRW vs ALLK Comparison
STRW vs ALLK Comparison
Compare STRW & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRW
- ALLK
- Stock Information
- Founded
- STRW 2015
- ALLK 2012
- Country
- STRW United States
- ALLK United States
- Employees
- STRW N/A
- ALLK N/A
- Industry
- STRW Real Estate Investment Trusts
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- STRW Real Estate
- ALLK Health Care
- Exchange
- STRW Nasdaq
- ALLK Nasdaq
- Market Cap
- STRW 92.9M
- ALLK 101.0M
- IPO Year
- STRW N/A
- ALLK 2018
- Fundamental
- Price
- STRW $10.60
- ALLK $1.12
- Analyst Decision
- STRW Strong Buy
- ALLK Hold
- Analyst Count
- STRW 1
- ALLK 5
- Target Price
- STRW $10.00
- ALLK $1.67
- AVG Volume (30 Days)
- STRW 216.7K
- ALLK 306.2K
- Earning Date
- STRW 11-08-2024
- ALLK 11-06-2024
- Dividend Yield
- STRW 5.04%
- ALLK N/A
- EPS Growth
- STRW 23.40
- ALLK N/A
- EPS
- STRW 0.51
- ALLK N/A
- Revenue
- STRW $112,050,000.00
- ALLK N/A
- Revenue This Year
- STRW N/A
- ALLK N/A
- Revenue Next Year
- STRW N/A
- ALLK N/A
- P/E Ratio
- STRW $20.26
- ALLK N/A
- Revenue Growth
- STRW 14.46
- ALLK N/A
- 52 Week Low
- STRW $6.56
- ALLK $0.54
- 52 Week High
- STRW $12.90
- ALLK $3.36
- Technical
- Relative Strength Index (RSI)
- STRW 42.39
- ALLK 52.99
- Support Level
- STRW $10.06
- ALLK $1.00
- Resistance Level
- STRW $10.55
- ALLK $1.11
- Average True Range (ATR)
- STRW 0.63
- ALLK 0.08
- MACD
- STRW -0.07
- ALLK 0.00
- Stochastic Oscillator
- STRW 37.14
- ALLK 47.73
About STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.